SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-301190
Filing Date
2023-12-21
Accepted
2023-12-21 16:09:31
Documents
18
Period of Report
2023-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d456025d8k.htm   iXBRL 8-K 34429
2 EX-1.1 d456025dex11.htm EX-1.1 196125
3 EX-4.1 d456025dex41.htm EX-4.1 75488
4 EX-5.1 d456025dex51.htm EX-5.1 13911
5 EX-99.1 d456025dex991.htm EX-99.1 9210
9 GRAPHIC g456025g1215202845649.jpg GRAPHIC 2533
10 GRAPHIC g456025g1215203402692.jpg GRAPHIC 3621
  Complete submission text file 0001193125-23-301190.txt   551592

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA annx-20231220.xsd EX-101.SCH 2848
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20231220_lab.xml EX-101.LAB 18758
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20231220_pre.xml EX-101.PRE 11709
12 EXTRACTED XBRL INSTANCE DOCUMENT d456025d8k_htm.xml XML 3469
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

IRS No.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 231505395
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)